Education
About Us
Working with TipRanks
Follow Us
Newron Pharmaceuticals SpA (CH:NWRN)
:NWRN
NWRN Stock Chart & Stats
CHF18.88
-CHF0.12(-1.32%)
At close: 4:00 PM EST
CHF18.88
-CHF0.12(-1.32%)
Day’s Range― - ―
52-Week RangeCHF5.20 - CHF19.72
Previous CloseN/A
Volume17.86K
Average Volume (3M)170.30K
Market Cap
$285.44M
Enterprise ValueCHF141.69M
Total Cash (Recent Filing)$43.20M
Total Debt (Recent Filing)$52.57M
Price to Earnings (P/E)11.9
Beta1.80
Next Earnings
Mar 17, 2026EPS Estimate
-1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding19,960,995
10 Day Avg. Volume255,106
30 Day Avg. Volume170,297
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)121.21
Price to Sales (P/S)3.44
P/FCF Ratio-10.03
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue2.37
Enterprise Value/Gross Profit2.37
Enterprise Value/Ebitda4.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Newron Pharmaceuticals SpA News
NWRN FAQ
What was Newron Pharmaceuticals SpA’s price range in the past 12 months?
Newron Pharmaceuticals SpA lowest stock price was CHF5.20 and its highest was CHF19.72 in the past 12 months.
What is Newron Pharmaceuticals SpA’s market cap?
Newron Pharmaceuticals SpA’s market cap is $285.44M.
When is Newron Pharmaceuticals SpA’s upcoming earnings report date?
Newron Pharmaceuticals SpA’s upcoming earnings report date is Mar 17, 2026 which is in 103 days.
How were Newron Pharmaceuticals SpA’s earnings last quarter?
Newron Pharmaceuticals SpA released its earnings results on Sep 16, 2025. The company reported CHF0 earnings per share for the quarter, beating the consensus estimate of -CHF0.38 by CHF0.38.
Is Newron Pharmaceuticals SpA overvalued?
According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Overvalued.
Does Newron Pharmaceuticals SpA pay dividends?
Newron Pharmaceuticals SpA does not currently pay dividends.
What is Newron Pharmaceuticals SpA’s EPS estimate?
Newron Pharmaceuticals SpA’s EPS estimate is -1.29.
How many shares outstanding does Newron Pharmaceuticals SpA have?
Newron Pharmaceuticals SpA has 19,960,995 shares outstanding.
What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?
Newron Pharmaceuticals SpA reported an EPS of CHF0 in its last earnings report, beating expectations of -CHF0.38. Following the earnings report the stock price went up 6.257%.
Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?
Currently, no hedge funds are holding shares in CH:NWRN
Company Description
Newron Pharmaceuticals SpA
Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for patients with central nervous system (CNS) disorders. The company specializes in addressing unmet medical needs in various areas, particularly in the treatment of conditions such as Parkinson's disease, schizophrenia, and pain management. Newron's core products include its lead candidate, safinamide, which has been approved for use in certain markets, and other pipeline candidates aimed at enhancing treatment outcomes in CNS disorders.
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Santhera Pharmaceuticals Holding
―
Xlife Sciences Ltd.
―
Options Prices
Currently, No data available
---